Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
Clinical trial NCT06996132 · RECRUITING
Trial details
- NCT number
- NCT06996132
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-09
- Primary completion
- 2027-05-30
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.